Clinical specialists from the University of Cape Town have issued a warning that some sports products, including pre-workout supplements, may contain dangerous concentrations of caffeine. This was published in the South African Medical Journal.
Clinical specialists from the University of Cape Town have issued a warning that some sports products, including pre-workout supplements, may contain dangerous concentrations of caffeine. This was published in the South African Medical Journal.
Since these supplements are often sold as patented mixtures with incomplete ingredient lists, it is extremely difficult for users to know exactly what they are consuming. Clinicians expressed concern regarding methylxanthine-mediated toxicity and emphasized that the growing popularity of such products requires 'enhanced regulatory oversight.'
Experts note that some pre-workout supplements may contain inaccurate amounts of caffeine and other stimulants, increasing the likelihood of adverse effects. Recently, one adult user experienced chest pain, rapid heartbeat, difficulty breathing, and vomiting after consuming a pre-workout supplement combined with an energy drink. Fortunately, the symptoms were managed with proper treatment.
However, clinicians warn that caffeine and related stimulants can cause tremors, agitation, tachycardia, low potassium levels, and, in severe cases, seizures or dangerous heart arrhythmias.
People planning to use pre-workout supplements are advised to check the caffeine and stimulant content, such as theophylline (which is naturally present in cocoa), and to be cautious of patented mixtures with undisclosed ingredient volumes. It is also necessary to avoid mixing supplements with energy drinks or other caffeine-containing products, and to be vigilant for signs such as chest pain, rapid heartbeat, tremors, vomiting, or shortness of breath after use.
The situation also points to a local regulatory gap. According to SAHPRA guidelines, certain complementary products are permitted to contain up to 300 mg of caffeine. Nevertheless, some manufacturers market these goods as food products, which places them outside of stricter control, so healthcare workers and fitness enthusiasts should remain vigilant about potential risks.
According to the first-of-its-kind study by the Indian Council of Medical Research (ICMR) under the i-DRONE initiative, using unmanned aerial vehicles to transport sputum samples from remote villages to tuberculosis (TB) testing centers can reduce diagnosis times by nearly two-thirds while minimizing patient travel expenses.
The study, conducted in the Yadadri-Bhuvanagiri district of Telangana state, demonstrated a significant improvement in indicators. The median time to receive TB diagnostic results decreased from 15 days to just five days after drones replaced traditional ground transport for sample delivery. On average, the diagnostic time reduced from 16.6 days to 6.9 days.
Furthermore, average out-of-pocket expenses for patients dropped from 9451 rupees to 91 rupees, representing a reduction of almost 99%. This study, published in the peer-reviewed journal IJTLD Open, assessed sample transportation using drones in real-world program conditions in collaboration with the National Tuberculosis Elimination Programme (NTEP).
Researchers from AIIMS Bibinagar, the ICMR's i-DRONE initiative, and AIIMS Bhubaneswar conducted this study. It became the first long-term program-based evaluation in India on the impact of drone logistics on TB diagnosis. The intervention covered 11 primary health centers, 60 sub-centers, and four TB units linked through a 'hub and spoke' network coordinated from AIIMS Bibinagar.
Patients could now submit sputum samples at the nearest medical facility instead of traveling 10–30 km to diagnostic centers. From there, drones delivered the samples to laboratories equipped with CBNAAT and Truenat machines.
The study involved 840 people: 206 during the traditional transport phase and 634 after the drones began operating. In addition to reducing diagnostic delays, there was a sharp increase in the reporting of TB test results the next day—from 1.5% to 76.3%. The percentage of patients waiting more than two days for results decreased from 92.2% to 16.3%.
Patients cited poor transport accessibility, travel difficulties, loss of income, and stigma associated with frequent visits to medical facilities as main reasons for diagnostic delays. Researchers noted that shifting sample transportation instead of moving patients significantly reduced both financial and logistical barriers.
The conclusion stated that integrating drones into the National Tuberculosis Elimination Programme can improve access to rapid diagnosis in rural, mountainous, and hard-to-reach areas, bringing India closer to the goal of eradicating tuberculosis. The authors acknowledged that the study was conducted only in one district, and long-term outcomes such as treatment adherence still require assessment; however, they emphasized that the data obtained proves the operational feasibility of drone-based logistics and its ability to strengthen equitable access to TB treatment.
Cervical cancer is becoming one of the most common problems among women in India after breast cancer, but there is a way to significantly reduce the risk of this disease.
Dr. Nilanchali Singh, Associate Professor in Obstetrics and Gynecology at AIIMS in New Delhi, notes that with timely vaccination, the risk of developing cervical cancer can be reduced by up to 95%. She emphasizes that in addition to vaccination, regular screening is crucial after reaching the age of 30.
Cervical cancer is a disease specific to women that develops in the lower part of the uterus, in the area of the cervix. Most cases are caused by a persistent infection with the human papillomavirus (HPV). This virus is transmitted from men to women through sexual contact. Usually, a woman's immune system eliminates this infection within a few months or years, but in some women, the infection persists for a long time and can gradually lead to cancer development.
If cancer is detected at an early stage, it can be cured, but if it progresses to an advanced stage, it can be fatal. Dr. Singh explains that the increase in cervical cancer cases is related both to improved diagnostic methods and to the increased frequency of HPV infection among women. Nevertheless, not every woman infected with HPV develops cancer; most cases are managed by the body's immune system. However, the risk increases in women with weakened immune systems or those who have been exposed to high-oncogenic HPV for a long time.
Since cervical cancer is caused by the HPV virus, vaccination against it helps reduce the threat of cancer. Although the vaccine is recommended for all women under 45, the optimal age for vaccination is considered to be between 9 and 14 years old. The vaccine can also be administered between the ages of 16 and 26, providing good protective effect. Women aged 26 to 45 can receive the vaccine upon a doctor's recommendation; although the level of protection at this age may be lower, this does not mean that the vaccination is useless.
Dr. Singh asserts that cervical cancer is one of the diseases that is largely preventable. If women get vaccinated and undergo regular tests after the age of 30, most cases can be stopped before they turn into cancer. In many countries, the introduction of the HPV vaccine has already led to a significant reduction in morbidity.
Regular diagnosis is equally important. Dr. Singh advises all women over 30 to undergo regular cervical cancer screening. Two types of tests are used for this: the Pap Smear Test and the HPV Test. Early detection allows for the treatment of cancer at an initial stage. It is also necessary to pay attention to certain signs:
Although these symptoms do not always indicate cancer, they are grounds for a mandatory medical examination.
